TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04267523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web parenting intervention
Description: Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group parenting intervention
Description: Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
Study: NCT03100929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
Study: NCT02650518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-course Antibiotics
Description: 3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Change
Description: Urinary catheter change once randomization is complete.
Study: NCT03279094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
Study: NCT03247634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting Ahead in a Just-Gettin'-By World
Description: The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
Study: NCT00390325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02382458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletters on cancer prevention and control
Description: E-mailed or mailed newsletters that provide information on how to prevent cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral program to reduce inflammation
Description: Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
Study: NCT02419742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
Study: NCT01127737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Completed surveys
Study: NCT02419742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
Study: NCT01127737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Completed surveys
Study: NCT03144596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride 10 MG
Description: Alfuzosin hydrochloride Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride 0.4 MG
Description: Tamsulosin Hydrochloride Tablet
Study: NCT01914042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Study: NCT03768596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vaccination form
Description: a form about vaccination
Study: NCT02106325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV of Ketamine (.25mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
Study: NCT04413188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm foot bath
Description: The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
Study: NCT03374228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified Dose on Specified Days
Study: NCT03223129

Intervention type: OTHER
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)

Intervention type: OTHER
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
Study: NCT00442507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Study: NCT03471884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonintubated thoracoscopic lobectomy
Description: Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubated thoracoscopic lobectomy
Description: Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
Study: NCT04313985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tennant Biomodulator-Pro™ Device
Description: Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tennant Biomodulator-Pro™ Device
Description: Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
Study: NCT01082159

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar decompression
Description: The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
Study: NCT00788606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, Rituximab
Description: 6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
Study: NCT04432415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Annual application od Silver Diamine Fluoride

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soduim Fluoride Varnish
Description: biannual apllication of Sodium Fluoride Varnish

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: biannual application of artificial saliva
Study: NCT03902626

Intervention type: OTHER
Intervention: Physiotherapy students

Intervention type: OTHER
Intervention: Medical students
Study: NCT01575704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise training (aerobic, resistance, flexibility), 5 times per week

Intervention type: OTHER
Group type: OTHER
Intervention: Mental Training
Description: Memorial/ mental training and relaxation, 5 times per week
Study: NCT03731741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: a known drug of xanthine derivatives used in intermittent claudication
Study: NCT04648904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
Study: NCT01986348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: One cycle is 28 days (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: One cycle is 28 days (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: One cycle is 28 days (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: One cycle is 28 days (4 weeks).
Study: NCT02868983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integration
Description: The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance
Study: NCT02429973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus rapamycin
Description: Gemcitabine and rapamycin given in combination
Study: NCT01542502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg daily subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily subcutaneous injection
Study: NCT02873897

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Session A: Experimental products (selected enriched products)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Experimental session: to select enriched products

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Session B: Control (standard products without enrichment)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control session
Study: NCT02009865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova
Description: Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
Study: NCT03768596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaccination form
Description: a form about vaccination
Study: NCT04453930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab，an engineered anti-PD-1 antibody
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administered at a dose of 250 mg during the maintenance phase.
Study: NCT02935894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological induction of sweating
Description: 15 minutes exercise at 60-80% oxygen consumption to induce sweating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
Study: NCT03531892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM300
Description: AJM300 film-coated tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to AJM300 tablets.
Study: NCT01821222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wired mothers
Description: The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider.
Study: NCT04335279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Description: Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
Study: NCT02981823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip replacement
Description: The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
Study: NCT04779463

Intervention type: DIAGNOSTIC_TEST
Intervention: Parasternal intercostal muscles thickness ultrasound indicies
Description: Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration.
Study: NCT03547206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201 Cohort A
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort A
Description: The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
Study: NCT01198132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebif
Description: Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Study: NCT01308424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL TML HSV
Description: Sublingual micro-dosing for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: sublingual dosing for 7 days
Study: NCT00839397

Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine
Description: Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI
Study: NCT02836548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: vorinostat 360 milligram once daily
Study: NCT02215967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
Study: NCT03547206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201 Cohort B
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cohort B
Description: The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
Study: NCT01118156

Intervention type: OTHER
Intervention: Education
Description: 75-minute training teaching utilization of new standardized suicide nomenclature
Study: NCT04419571

Intervention type: PROCEDURE
Intervention: Emergency Laparotomy
Description: All adult patients undergoing emergency laparotomy

Intervention type: PROCEDURE
Intervention: Emergency Laparotomy
Description: All adult patients undergoing emergency laparotomy
Study: NCT03602807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra
Study: NCT03720028

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Describe communication and sensory profile using standardized tests and observations.

Intervention type: BEHAVIORAL
Intervention: Parental experiences
Description: Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
Study: NCT03949959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
Study: NCT00704548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Simvastatin once daily, orally in the morning period, during eigth weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily, orally in the morning period, during eigth weeks
Study: NCT00703612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Stem cells
Description: Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.